TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $15.80 million. The enterprise value is $18.15 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.53 million shares outstanding. The number of shares has increased by 9.82% in one year.
| Current Share Class | 11.53M |
| Shares Outstanding | 11.53M |
| Shares Change (YoY) | +9.82% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.58% |
| Owned by Institutions (%) | 13.54% |
| Float | 9.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.79 |
| Forward PS | n/a |
| PB Ratio | 0.58 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.03, with a Debt / Equity ratio of 0.27.
| Current Ratio | 2.03 |
| Quick Ratio | 1.40 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.39% and return on invested capital (ROIC) is -8.46%.
| Return on Equity (ROE) | -14.39% |
| Return on Assets (ROA) | -6.65% |
| Return on Capital (ROIC) | -8.46% |
| Revenue Per Employee | $1.60M |
| Profits Per Employee | -$3.32M |
| Employee Count | 1 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -43,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.81% in the last 52 weeks. The beta is 1.14, so TherapeuticsMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -50.81% |
| 50-Day Moving Average | 1.56 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 33.44 |
| Average Volume (20 Days) | 23,691 |
Short Selling Information
The latest short interest is 29,735, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 29,735 |
| Short Previous Month | 23,478 |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.32% |
| Short Ratio (days to cover) | 2.23 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $1.60 million and -$3.32 million in losses. Loss per share was -$0.29.
| Revenue | 1.60M |
| Gross Profit | 1.60M |
| Operating Income | -4.79M |
| Pretax Income | -6.13M |
| Net Income | -3.32M |
| EBITDA | -4.55M |
| EBIT | -4.79M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $5.05 million in cash and $7.40 million in debt, giving a net cash position of -$2.35 million or -$0.20 per share.
| Cash & Cash Equivalents | 5.05M |
| Total Debt | 7.40M |
| Net Cash | -2.35M |
| Net Cash Per Share | -$0.20 |
| Equity (Book Value) | 27.09M |
| Book Value Per Share | 2.35 |
| Working Capital | 6.18M |
Full Balance SheetCash Flow
| Operating Cash Flow | -7.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.12M |
| FCF Per Share | -$0.62 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -300.19% and -207.77%.
| Gross Margin | 100.00% |
| Operating Margin | -300.19% |
| Pretax Margin | -251.25% |
| Profit Margin | -207.77% |
| EBITDA Margin | -284.77% |
| EBIT Margin | n/a |
| FCF Margin | -942.87% |